Efficacy of immunosuppressants with bridge vasodilator therapy in severe lupus erythematosus‐associated pulmonary arterial hypertension
Abstract Optimal management of systemic lupus erythematosus (SLE)‐associated pulmonary arterial hypertension (PAH) remains unclear. Our observation describes the case of a 31‐year‐old SLE patient presenting with cardiogenic shock revealing severe PAH, in which a therapeutic scheme combining immunosu...
Main Authors: | Sébastien Sanges, Laurent Savale, Nicolas Lamblin, Martine Rémy‐Jardin, Marc Humbert, Vincent Sobanski |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12507 |
Similar Items
-
Preliminary safety and immunogenicity of Zostavax vaccine in mild-moderately immunosuppressed systemic lupus erythematosus patients, and healthy controls
by: Cogman, Abigail Rachel
Published: (2016) -
Towards Precision Medicine in Systemic Lupus Erythematosus
by: Lever E, et al.
Published: (2020-02-01) -
Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies
by: Tselios K, et al.
Published: (2016-12-01) -
Cutaneous lupus erythematosus: An update
by: Carina M Grönhagen, et al.
Published: (2014-01-01) -
Talaromyces marneffei Infection in Systemic Lupus Erythematosus Patients: Report of Two Cases and Review of the Literature
by: Wei J, et al.
Published: (2020-10-01)